Skip to content
10-Q

Quarterly Report

Forte Biosciences, Inc. FBRX

0000950170-25-072569

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q1 2025 · Mar 31, 2025 $45.86M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $22.24M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.03M
Current Liabilities Q1 2025 · Dec 31, 2024 $9.08M
Current Assets Q1 2025 · Mar 31, 2025 $47.16M
Current Assets Q1 2025 · Dec 31, 2024 $61.35M
Total Assets Q1 2025 · Mar 31, 2025 $47.46M
Total Assets Q1 2025 · Dec 31, 2024 $61.56M
Short Term Investments Q1 2025 · Dec 31, 2024 $36.12M
Capex Q1 2025 · Mar 31, 2024 $6K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$6.67M
Stockholders Equity Q1 2025 · Mar 31, 2024 $28.69M
Stockholders Equity Q1 2025 · Dec 31, 2023 $35.31M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$4.03
Eps Basic restated Q1 2025 · Mar 31, 2024 −$4.03
Sga Expense Q1 2025 · Mar 31, 2024 $3.45M
Net Income Q1 2025 · Mar 31, 2024 −$7.42M
Operating Income Q1 2025 · Mar 31, 2024 −$7.8M